Lundbeck retained at neutral by Merrill

Lundbeck was retained by Merrill Lynch analyst Erica Whittaker at a neutral rating with a value of DKK 134 per share. Merrill looks for some upside potential if Lundbeck settles the U.S. patent litigation on Lexapro, Forest's antidepressant drug. The trial begins March 20. Lundbeck's long-term growth depends on the insomnia drug gaboxadol, expected to be launched in 2008 by Merck, as patents for its other drugs expire. Shares of the Copenhagen, Denmark, pharmaceutical company were down DKK 0.25, or 0.19%, at DKK 82.59 on volume of 699,131 shares versus the three-month running average of 961,248 shares. (Copenhagen: LUN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.